Introduction
CD30 (TNFRSF8) is a transmembrane glycosylated protein and member of the tumor necrosis factor receptor superfamily (1) . Within the hematopoietic system, this receptor is expressed by only a few activated T and B cells in lymphoid tissues (2) . CD30 is also expressed by some EBV-infected B cells in infectious mononucleosis, but is virtually absent on peripheral blood B cells (1) (2) (3) . Little is known about the specific features of CD30 + B cells. These cells are large mononuclear cells that are found within germinal centers (GCs), as well as in extrafollicular (EF) regions of lymph nodes (2, 4) . CD30
+ EF B cells express the B cell transcription factor PAX5, the plasmablast/plasma cell factor IRF4, and JUNB, a member of the AP-1 transcription factor family (4, 5) . A fraction of them expresses activation-induced cytidine deaminase (AID), a key factor for somatic hypermutation and class switch recombination (4, 5) .
Being a hallmark of Hodgkin and Reed/Sternberg (HRS) tumor cells in classical Hodgkin lymphoma (cHL), CD30 is an important marker in lymphoma diagnosis (6) . CD30-expressing tumor cells are also characteristic for primary mediastinal B cell lymphoma, a fraction of conventional diffuse large B cell lymphomas (DLBCLs), and anaplastic large cell lymphoma (1, (6) (7) (8) . The expression of CD30 by malignant B and T cells in cHL and other lymphomas is not only of biological and diagnostic relevance, but has also recently gained major impact for the treatment of these tumors. An anti-CD30 antibody coupled to a microtubule inhibitor (brentuximab vedotin) shows promising results in the eradication of CD30 + lymphoma cells and is currently being tested in numerous clinical studies (9) (10) (11) .
We isolated human tonsillar CD30 + B cells, characterized the cells phenotypically, analyzed their rearranged IGHV genes, and compared their global gene expression to that of the main subsets of normal mature B cells and of cHL HRS cells. We aimed to clarify the differentiation stage and specific features of normal CD30 + B cells and their relationship to cHL HRS cells.
Results

Normal CD30 + GC and EF B cells are mostly CD27 + and classswitched. Previous immunohistochemical analyses recognized large CD30
+ B cells inside GCs and outside of follicles (2, 4) . Accordingly, we distinguished CD30 + GC B cells (CD20 hi CD38 + ) and CD30
+ EF B cells (CD20 + CD38 lo/-) by flow cytometry ( Figure  1A ). Typically, only 0.1%-1.7% (mean 0.7%) of tonsillar mononuclear cells are CD30 + B cells (Supplemental Table 1 ; supplemental material available online with this article; https://doi. org/10.1172/JCI95993DS1). We analyzed CD30 + B cells for the expression of CD27, a marker for memory B cells, GC B cells, and plasma cells (12, 13) . Most cells of both CD30 + B cell subsets express CD27 levels similar to those in conventional GC and memory B cells (Supplemental Figure 1) . The Ig isotype distribution of CD30 + GC and EF B cells was largely similar (Supplemental Table 2 ): on average, about 50% of CD30 + GC and EF B cells expressed IgG, and about 20% of both subsets are IgA + ( Figure  1 and Supplemental Table 2 ). On average, IgM was expressed in + GC and EF B cells (n = 5 each) and compared them with profiles of tonsillar naive B cells (n = 5), memory B cells (n = 5), plasma cells (n = 5), and conventional GC B cells (n = 10) (15, 16 + GC B cells were somatically mutated, with average mutation frequencies between 4.6% and 8% (Table 1) . This is slightly higher than mutation frequencies typically observed for tonsillar GC B cells (14) . The Ig framework region replacement-to-silent (R/S) ratio of mutations was lower than 2 in 3 of the 4 samples (2.4 in donor 3), in line with positive selection of a functional B cell receptor (BCR) (14) . We found several clonally related V H gene sequences in 3 of the 4 samples, indicating that CD30 + GC B cells can be members of expanded clones. The IGVH gene analysis of CD30 + EF B cells from 3 donors showed between 79% and 92% mutated sequences, whereas cells from 1 donor had only 33% mutated IGVH gene sequences. Tonsillar mononuclear cells were depleted  of CD3  + T cells and enriched for CD30  + B cells by  consecutive MACS isolation steps. (A) CD3  -CD30-enriched B cells were stained for CD20, CD30,  CD38, and either (Figure 2A ), so we defined the specific features of the former. Fifteen genes were significantly lower expressed in CD30 + GC B cells (fold change [FC] ≥ 3, P < 0.01, FDR < 0.05; Supplemental Table 5 ), including well-known B cell differentiation markers such as FCRL3, FCRL1, CD24, FOXP1, AICDA, and BACH2. Of note, the latter 3 genes are also downregulated during centroblast to centrocyte transition (18) (19) (20) . Ninety-eight genes were significantly higher expressed in CD30 + GC B cells, including IL2RB, CCL22, BATF3, MYC, the MYC cooperating factor CCDC86, and the antiapoptotic factors LRPPRC and PRELID1. Increased expression of IL2RB by CD30 + GC B cells was validated at the protein level by flow cytometry (Supplemental Figure 2A) . Also, mRNA expression of IL21R, another key factor for B cell-T cell interaction in the GC, was significantly upregulated by CD30 + GC B cells (albeit only 1.8-fold) and hence analyzed by flow cytometry. Indeed, CD30 + GC B cells showed significantly higher IL21R surface expression than conventional GC B cells (Supplemental Figure 2B ). IL2RB and CCL22 are upregulated in centrocytes upon T helper (Th) cell interaction, suggesting a link between CD30 + GC B cells and centrocytes (21, 22) . In agreement, centrocyte-specific genes were more highly expressed than centroblast-specific genes by GSEA in CD30
+ GC B cells relative to conventional GC B cells (Supplemental Figure 3A) . Moreover, MYC, a master regulator of proliferation and metabolism (23) We then sought to identify genes differentially expressed between the 2 CD30 + B cell subsets. Many of the 19 genes with at least 3-fold higher expression in CD30 + GC B cells encode wellknown GC B cell markers (e.g., BCL6, MYBL1, LCK, RGS13, S1PR2, and KLHL6) (P < 0.05, false discovery rate [FDR] < 0.05, Supplemental Table 3 For calculation of the average mutation frequency, sequences with only 1 mutation were not considered as mutated, as polymerase errors cannot be excluded. Identical sequences were counted once, as they might derive from 1 cell. In case of intraclonal diversity, each unique sequence was counted once. Both in-frame and out-of-frame rearrangements and only mutated sequences were considered. Insertions and deletions were calculated as 1 mutation.
B
For calculation of the R/S ratio, only in-frame rearrangements were considered. C We analyzed the sequences for crippling mutations that render originally functional IgV region genes nonfunctional, as such crippling mutations are seen in 25% of cHL cases (33) . However, only 2 CD30
+ GC B cells and 1 CD30 + EF B cell carried such mutations. Therefore, we cannot exclude that these represent PCR errors.
D
This donor might contain 2 additional clones with 2 cells per clone each. As they carry only 1 distinct mutation, we cannot exclude a PCR error and therefore they are not counted as distinct clones. cell differentiation factors, including CD24, which is downregulated upon plasma cell differentiation (29) . Also in comparison to plasma cells, CD30 + EF B cells have many more genes upregulated than downregulated (Supplemental Table 7 ). Again, numerous genes involved in proliferation are higher expressed by CD30 + EF B cells, as are E2F and MYC motifbased gene sets (Supplemental Table 4 and Supplemental Figure  3 , B-D). Plasma cells have significantly higher levels of Ig heavy and light chain transcripts and the typical plasma cell markers XBP1 and CD38. Collectively, CD30
+ EF B cells display characteristics of T cell interactions, cell survival, and proliferative or proliferation-prone features.
Recently, a distinct subset of human CD21 lo post-GC B cells was described that are recent GC graduates primed for plasma cell differentiation (30) . The CD30
+ EF B cells also show lower CD21 surface expression than conventional memory B cells (Supplemental Figure 2C ). However, for other key features, the 2 types of B cells clearly differ from each other (Supplemental Figure 2D) . We therefore conclude that the CD30 + EF B cells are distinct from the CD21 lo recent GC emigrants. We confirmed high MYC activity in CD30 + versus conventional GC B cells, and in CD30 + EF versus memory B cells or plasma cells (Figure 3, A-D) , using functionally validated sets of MYC target genes in human B cells and a set of genes upregulated enriched in CD30 + EF B cells (Supplemental Table 4 ), reflecting increased metabolic demands of the highly active and proliferating CD30 + EF B cells. In addition, genes engaged in T cell interaction(s) were upregulated in CD30 + EF B cells: CCL22 and CXCL10 attract CD4 + Th cells (25, 26) , and IL2RB and IL21R are receptors for interleukins produced by Th cells. By flow cytometry, we confirmed higher surface expression of IL2RB and IL21R on CD30 + EF B cells than on memory B cells (Supplemental Figure  2) . Of note, some antiapoptotic factors were highly expressed by CD30 + EF B cells, such as BIRC5, which is upregulated in plasmablasts (27) , and the chemokine macrophage migration inhibitory factor (MIF). MIF binds to the CD44/CD74 complex on B cells and promotes their survival (28 Next, we sought to identify genes differentially expressed between CD30
+ EF B cells and HRS cells. We found 169 genes with at least 5-fold higher expression in CD30 + EF B cells and 73 genes with at least 3-fold higher expression in HRS cells (Supplemental Table 8 ). These genes largely overlap with those deriving from the comparison of CD30 + GC B cells and HRS cells, which was expected, given the high overall similarity of the 2 normal CD30 + B cell subsets (Supplemental Table 9 ). Genes expressed at higher levels in HRS cells reflected well-known pathophysiological features of these cells, including components and regulators of the extracellular matrix (e.g., collagen, fibronectin, metallopeptidases, and cathepsins), numerous chemokines (e.g., CCL3, CCL5, CCL17), and several non-B cell markers (e.g., CD3δ, LAT, granzyme B, and the NK-cell factor ID2) (33) .
The genes higher expressed in CD30 + EF B cells than in HRS cells included numerous B cell factors (e.g., CD20, BOB1, EBF1, BLNK) (Supplemental Table 8 ), in line with the downregulation of the B cell expression program in HRS cells (34) . Strikingly, 30 of the 169 genes at least 5-fold lower expressed in HRS than in CD30 + EF B cells play roles in cell-cycle and spindle apparatus, genomic stability, cytokinesis, DNA repair, or polyploidy (Supplemental Table  8 ). Multinuclearity is a hallmark of the Reed/Sternberg cells, hence we compared the expression of 12 genes regulating spindle apparatus, cytokinesis, and polyploidy in CD30 + EF B and HRS cells with their expression in conventional GC B cells, DLBCL, and FL (Figure 4E) . Downregulation of these important regulators in HRS cells is also seen in comparison to conventional GC B cells, and is more pronounced in HRS cells than in the 2 other types of lymphomas included for comparison (Supplemental Table 8 ). Thus, the strong downregulation of key factors regulating cytokinesis and the spindle apparatus is a specific feature of HRS cells.
We then compared CD30 + GC and EF B cells with HRS cells by GSEA to identify pathway and transcription factor gene sets differentially expressed between these cells. In line with the lost B cell phenotype of HRS cells, several B cell transcription factorrelated gene sets (e.g., PAX5, MYB, YY1, and ERG) were significantly enriched in CD30 + B cells, as were E2F and MYC signatures (Supplemental Table 10 ). Moreover, motif-based gene sets of AP-1 family members MAF and ATF3 were enriched in CD30 + B cells, suggesting strong AP-1 activity in these cells (Supplemental Table   Figure murine centrocytes expressing MYC and the transcription factor AP-4 has higher transcript levels of CD30 than MYC -GC B cells (47) (not mentioned in the text of that study, but retrievable from the RNA-Seq data), suggesting that CD30 may also serve as a surface marker for these cells in the mouse.
An additional feature of CD30 + GC B cells is upregulated expression of the transcription factor BATF3, which is a member of the AP-1 transcription factor family, as is JUNB, which is also expressed by CD30 + B cells (4) . Thus, AP-1 activity appears to be a specific feature of CD30 + GC B cells. Notably, AP-1 is an activator of CD30 transcription (48, 49) + GC B cells revealed that they express key GC B cell factors, validating their GC B cell identity. Their striking dissimilarity to conventional GC B cells was mainly due to their upregulation of hundreds of genes. A major reason for this is likely their strong expression and activity of MYC, which is an amplifier of gene expression (38, 39) .
Expression of MYC by CD30
+ GC B cells has been reported recently; however, that study was restricted to immunohistochemical analysis and did not investigate MYC activity or the overall gene expression pattern of these cells (40) . Here we show that MYC activity in CD30 + GC B cells links them to a specific transitional state of GC B cell differentiation. Transgenic mouse studies characterized MYC + centrocytes, a small subset of positively selected light zone cells in established GCs that is preparing for a return to the dark zone to become proliferating centroblasts again (41, 42) . Our findings support the idea that human CD30 + GC B cells are positively selected centrocytes preparing to become proliferating centroblasts again ( Figure 5A ). First, genes involved in B cell-T cell interaction, which is essential for B cell selection in the light zone, were higher expressed in CD30 + GC than conventional GC B cells. Second, centrocyte-specific genes were higher expressed in CD30
+ GC B cells than in conventional GC B cells (remarkably despite the many proliferative genes expressed by CD30 + GC B cells). Third, factors that are downregulated in late GC B cells (AID, BACH2, MYBL1) (18, 19) were also expressed at lower levels in CD30 + than in conventional GC B cells. Fourth, prosurvival factors such as LRPPRC and PRELID1 (43, 44) were expressed at elevated levels in CD30 + GC B cells, potentially reflecting positive selection of these cells. Fifth, CD30
+ GC B cells upregulate many physiological genes, preparing them for high proliferation and metabolic demands. In addition, immunohistochemical studies for the location of CD30 + and/or MYC + human GC cells revealed that these cells are mostly positioned in the apical light zone and at the periphery of the GC (1, 4, 40, 45, 46) , in line with their identity as centrocytes initiating their return to the dark zone. We conclude that human CD30 + GC B cells represent MYC + centrocytes, positively selected and undergoing a cyclic reentry into the centroblast pool, thereby sustaining the GC reaction. Of note, a subset of
jci.org Volume 128 Number 7 July 2018 apparatus, and cytokinesis ( Figure 4E ). HRS cells show high genomic instability, and the generation of bi-or multinucleated Reed/Sternberg cells by a process of incomplete cytokinesis and refusion of daughter cells is a hallmark of cHL (57, 58) . Hence, suppression of these factors may, perhaps cooperatively, account for this key pathobiological feature of cHL. Our finding that CD30 + GC B cells represent the MYC + subset of centrocytes is also of clinical relevance, as numerous patients affected by B or T cell lymphomas with CD30 + tumor cells are currently treated with the anti-CD30 antibody brentuximab vedotin, which eradicates CD30-expressing cells (9-11, 59 ). Considering that elimination of MYC + centrocytes in the mouse leads to a breakdown of the GC reaction (41, 42) , treatment of patients with lymphoma with brentuximab vedotin may impair T-dependent humoral immune responses, which should be closely monitored in clinical studies.
Methods
Isolation and phenotypic characterization of CD30
+ B cells from tonsils. Table 3 and Supplemental Table 8 ). Moreover, CD30
+ EF B cells and HRS cells share a strong NF-κB signature, which is less pronounced in CD30 + GC B cells (Supplemental Table 4 ) (51). NF-κB and JAK/STAT activities in HRS cells are not only mediated by stimuli from other cells in the microenvironment but are also due to numerous genetic lesions and/or EBV infection in a fraction of cases (32) . Moreover, MYC activity in HRS cells is at least partly mediated through STAT3/5 activation via induction of the AP-1 family member BATF3, which directly induces MYC transcription in HRS cells (52) . In the course of their malignant transformation, GC B cell-specific features were lost by HRS cells and NF-κB activity was increased due to genetic lesions, so that they resemble post-GC EF CD30 + B cells more than CD30
+ GC B cells. Thus, we propose a scenario in which HRS cells derive from crippled GC B cells that manage to escape apoptosis by differentiating into the direction of CD30 + B cells and acquiring key features of these cells ( Figure 5B ). In this sense, CD30 + B cells can be considered the origin of HRS cells.
Assuming that CD30 + B cells are the specific cellular origin of HRS cells, a comparison of these cells can reveal which features of HRS cells reflect physiological characteristics of their cellular origin and which hallmarks of HRS cells can be considered as aberrant and disease-specific. MYC activity, as known for HRS cells (16, 53) , is also seen in normal CD30 + B cells, and at even higher levels. Similarly, STAT activities, which are hallmarks of HRS cells (36, 37, 54) , now turn out not to be aberrant, as normal CD30 + B cells can also show STAT activity. A further similarity between CD30 + normal B cells and HRS cells is expression and presumably activity of AP-1 family members. JUN, JUNB, and ATF3 expression and their role for survival of HRS cells are well-known (55, 56) . Moreover, we recently identified high expression and activity of BATF3 as being essential for survival of HRS cells (52) . As CD30 + B cells also express BATF3 as well as JUNB (4) Statistics. The statistical analysis was performed as described elsewhere (15, 62) . The CD30 + B cell samples were isolated and processed later than the samples of GSE14879, but a coanalysis of newly processed conventional GC B cells and CD30 + B cells revealed that there was no strong batch effect after normalization, so that the new CD30 + samples could be included in the prior set without having to apply a batch correction. Statistical analysis was performed using the computing environment R (R Development Core Team, 2005). Additional software packages (affy, geneplotter, multtest, vsn) were taken from the Bioconductor project (63) . For microarray preprocessing, the variance stabilization method of Huber et al. was applied for probe level normalization (64) . The variance of probe intensities is rendered independent of their expected expression levels by this method. Assuming that the majority of genes are not differentially expressed across the samples, parameters (offset and a scaling factor) were estimated for each microarray. With regard to the computational complexity of the algorithm, parameters are estimated on a random subset of probes and are then used to transform the complete arrays. By application of the robust median polish method on the normalized data probe set, summarization was calculated. Considering the different probe affinities via the probe effect, an additive robust model on the logarithmic scale (base 2) was fitted across the arrays for each probe set (65, 66) .
Unsupervised hierarchical clustering was performed for the probe sets with a standard deviation greater than 1 across all samples using the Manhattan distance and the average linkage method. The stability of the resulting dendrogram was tested with Pvclust (67) .
For differential gene expression analysis, to reduce the dimension of the microarray data before conducting pairwise comparisons, an intensity filter (the signal intensity of a probe had to be ≥100 in at least 25% of the samples, if the group sizes were equal) and a variance filter (the interquartile range of log 2 intensities should be ≥0.5, if the group sizes were equal) were applied. In case of unequal group sizes, the signal intensity of a probe set had to be above 100 in at least a fraction (smaller group size minus 1, divided by the total sample size of the 2 groups) of samples. The interquartile range of log 2 intensities had to be at least 0.1 for unequal group sizes. After global filtering, a 2-sample t test was applied to identify genes that were differentially expressed between 2 groups. The FDR according to Benjamini and Hochberg was used to account for multiple testing (68) . FC between the 2 groups of each supervised analysis was calculated for each gene. PCA was performed using preselected gene sets (unsupervised with SD filter or significant differentially expressed genes) and predecided groups of samples. The first and second principal components are visualized in a 2D plot. For the other statistical evaluation, either a paired or unpaired 2-tailed t test was used, as specified in the respective figure legends. A P value smaller than 0.05 was considered significant.
Study approval. As approved by the local ethics committee of the Medical School of the University Duisburg-Essen, all samples were collected with the informed consent of the donors. Written informed consent was received from participants prior to inclusion in the study.
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